PURPOSE: The objective of our study was to evaluate the presence of respiratory symptoms and chronic obstructive pulmonary disease (COPD) in a human immunodeficiency virus (HIV)-infected outpatient population and to further investigate the role of highly active antiretroviral therapy (HAART) and other possibly associated risk factors. METHODS: We consecutively enrolled in a cross-sectional study HIV-infected patients and HIV-negative age, sex and smoking status matched controls. All participants completed a questionnaire for pulmonary symptoms and underwent a complete spirometry. RESULTS: We enrolled 111 HIV-infected patients and 65 HIV-negative age- and sex-matched controls. HIV-infected patients had a significantly higher prevalence of any respiratory symptom (p = 0.002), cough (p = 0.006) and dyspnoea (p = 0.02). HIV-infected patients also had a significantly higher prevalence of COPD in respect of HIV-negative controls (p = 0.008). Furthermore, HIV-infected individuals had significantly (p = 0.002) lower forced expiratory volume at one second (FEV1) and FEV1/forced vital capacity (FVC) ratio (Tiffeneau index) (p = 0.028), whereas the total lung capacity (TLC) was significantly higher (p = 0.018). In the multivariate analysis, significant predictors of respiratory symptoms were current smoking [adjusted odds ratio (AOR) 11.18; 95 % confidence interval (CI) 3.89-32.12] and previous bacterial pneumonia (AOR 4.41; 95 % CI 1.13-17.13), whereas the only significant predictor of COPD was current smoking (AOR 5.94; 95 % CI 1.77-19.96). HAART receipt was not associated with respiratory symptoms nor with COPD. CONCLUSIONS: We evidenced a high prevalence of respiratory symptoms and COPD among HIV-infected patients. HIV infection, current cigarette smoking and previous bacterial pneumonia seem to play a significant role in the development of respiratory symptoms and COPD. Thus, our results suggest that the most at-risk HIV-infected patients should be screened for COPD to early identify those who may need specific treatment.
PURPOSE: The objective of our study was to evaluate the presence of respiratory symptoms and chronic obstructive pulmonary disease (COPD) in a human immunodeficiency virus (HIV)-infectedoutpatient population and to further investigate the role of highly active antiretroviral therapy (HAART) and other possibly associated risk factors. METHODS: We consecutively enrolled in a cross-sectional study HIV-infectedpatients and HIV-negative age, sex and smoking status matched controls. All participants completed a questionnaire for pulmonary symptoms and underwent a complete spirometry. RESULTS: We enrolled 111 HIV-infectedpatients and 65 HIV-negative age- and sex-matched controls. HIV-infectedpatients had a significantly higher prevalence of any respiratory symptom (p = 0.002), cough (p = 0.006) and dyspnoea (p = 0.02). HIV-infectedpatients also had a significantly higher prevalence of COPD in respect of HIV-negative controls (p = 0.008). Furthermore, HIV-infected individuals had significantly (p = 0.002) lower forced expiratory volume at one second (FEV1) and FEV1/forced vital capacity (FVC) ratio (Tiffeneau index) (p = 0.028), whereas the total lung capacity (TLC) was significantly higher (p = 0.018). In the multivariate analysis, significant predictors of respiratory symptoms were current smoking [adjusted odds ratio (AOR) 11.18; 95 % confidence interval (CI) 3.89-32.12] and previous bacterial pneumonia (AOR 4.41; 95 % CI 1.13-17.13), whereas the only significant predictor of COPD was current smoking (AOR 5.94; 95 % CI 1.77-19.96). HAART receipt was not associated with respiratory symptoms nor with COPD. CONCLUSIONS: We evidenced a high prevalence of respiratory symptoms and COPD among HIV-infectedpatients. HIV infection, current cigarette smoking and previous bacterial pneumonia seem to play a significant role in the development of respiratory symptoms and COPD. Thus, our results suggest that the most at-risk HIV-infectedpatients should be screened for COPD to early identify those who may need specific treatment.
Authors: Kristina Crothers; Tephany A Griffith; Kathleen A McGinnis; Maria C Rodriguez-Barradas; David A Leaf; Sharon Weissman; Cynthia L Gibert; Adeel A Butt; Amy C Justice Journal: J Gen Intern Med Date: 2005-12 Impact factor: 5.128
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Kristina Crothers; Laurence Huang; Joseph L Goulet; Matthew Bidwell Goetz; Sheldon T Brown; Maria C Rodriguez-Barradas; Krisann K Oursler; David Rimland; Cynthia L Gibert; Adeel A Butt; Amy C Justice Journal: Am J Respir Crit Care Med Date: 2010-09-17 Impact factor: 21.405
Authors: S Leone; G Gregis; G Quinzan; D Velenti; G Cologni; L Soavi; V Ravasio; D Ripamonti; F Suter; F Maggiolo Journal: Infection Date: 2011-01-19 Impact factor: 3.553
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: A T Chin; J Rylance; S Makumbirofa; S Meffert; T Vu; J Clayton; P Mason; P Woodruff; J Metcalfe Journal: Int J Tuberc Lung Dis Date: 2019-02-01 Impact factor: 2.373
Authors: Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: D R Bailey Miles; Usama Bilal; Heidi E Hutton; Bryan Lau; Catherine R Lesko; Anthony Fojo; Mary E McCaul; Jeanne Keruly; Richard D Moore; Geetanjali Chander Journal: J Health Care Poor Underserved Date: 2019